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TRPC1/4/5 channels are non-specific cation channels implicated in a wide variety of dis-
eases, and TRPC1/4/5 inhibitors have recently entered clinical trials. However, fundamental
and translational studies require a better understanding of TRPC1/4/5 channel regulation by
endogenous and exogenous factors. Although several potent and selective TRPC1/4/5
modulators have been reported, the paucity of mechanistic insights into their modes-of-
action remains a barrier to the development of new chemical probes and drug candidates.
Xanthine-based modulators include the most potent and selective TRPC1/4/5 inhibitors
described to date, as well as TRPC5 activators. Our previous studies suggest that xanthines
interact with a, so far, elusive pocket of TRPC1/4/5 channels that is essential to channel
gating. Here we report the structure of a small-molecule-bound TRPC1/4/5 channel—human
TRPC5 in complex with the xanthine Pico145—to 3.0 Å. We found that Pico145 binds to a
conserved lipid binding site of TRPC5, where it displaces a bound phospholipid. Our findings
explain the mode-of-action of xanthine-based TRPC1/4/5 modulators, and suggest a struc-
tural basis for TRPC1/4/5 modulation by endogenous factors such as (phospho)lipids and
Zn2+ ions. These studies lay the foundations for the structure-based design of new gen-
erations of TRPC1/4/5 modulators.
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Transient Receptor Potential Canonical (TRPC) proteinsform homo- or heterotetrameric, non-selective cationchannels permeable by Na+ and Ca2+1–6. Based on
sequence similarity, the mammalian TRPC proteins can be fur-
ther divided into sub-groups: TRPC1/4/5, TRPC3/6/7 and
TRPC27, the latter of which is encoded by a pseudogene in
humans8. TRPC4 and TRPC5 are the most closely related TRPC
proteins9 (70% sequence identity) and can form functional,
homomeric TRPC4:C4 and TRPC5:C5 channels10. TRPC1 (48%
and 47% sequence identity to TRPC4 and TRPC5, respectively) is
not thought to form functional homomeric channels but is widely
expressed and an important contributor to heteromeric TRPC1/
4/5 ion channels10–15.
Although disruption of the Trpc4/5 genes16 and global
expression of a dominant-negative mutant TRPC512 do not cause
catastrophic phenotypes in rodents, TRPC1/4/5 channels have
been implicated in a wide range of physiological and pathological
mechanisms4,5,10,17. These findings have driven the development
of potent and selective TRPC1/4/5 modulators as chemical probes
and drug candidates5,10,18, and clinical trials have been started by
Hydra Biosciences/Boehringer Ingelheim (the TRPC4/5 channel
inhibitor BI 135889 for treatment of anxiety/CNS disorders) and
Goldfinch Bio (the TRPC5 channel inhibitor GFB-887 for
genetically driven kidney disease).
Physiological activation and modulation of TRPC1/4/5 channel
activity is complex4–6 and may include mediation by endogenous
and dietary lipids12,19–22 and metal ions such as Zn2+23. In
addition, structurally diverse pharmacological modulators have
been reported5,10,18, including inhibitors suitable for studies of
TRPC1/4/5 in cells, tissues and animal models such as the xan-
thines Pico145 (also called HC-608)24–26 and HC-07025,26, the
pyridazinone derivative GFB-843827, and the benzimidazole
ML20428. However, structural insight into the mode-of-action of
small-molecule TRPC1/4/5 modulators is lacking, and no small-
molecule-binding sites have been identified.
Currently, the most potent and selective TRPC1/4/5 inhibitor
is the xanthine Pico145, which inhibits the channels with IC50
values in the picomolar to the low nanomolar range and displays
the highest potency against heteromeric channels24. Pico145 is
orally bioavailable and has been used successfully for studies of
TRPC1/4/5 channels in vivo26,29,30. Detailed characterisation of
Pico145 and the related xanthine AM237—a partial TRPC5
agonist that inhibits other TRPC1/4/5 channels31—revealed that:
(1) Pico145 and AM237 act rapidly and reversibly in outside-out
excised patch recordings, highlighting a membrane-delimited
effect24,31; (2) Pico145 is a competitive antagonist of (−)-englerin
A (EA)24 and AM23731, and also inhibits channel activation
by sphingosine-1-phosphate (S1P), carbachol and Gd3+24,25,
although picomolar concentrations of Pico145 can potentiate
Gd3+-induced TRPC4 currents as well24; (3) Pico145
concentration-dependently inhibits photoaffinity labelling of
TRPC5 by the xanthine-based photoaffinity probes Pico145-
DAAlk and Pico145-DAAlk2, with IC50 values in the same range
as inhibition of TRPC5-mediated calcium influx32. These results
provide evidence that these xanthines modulate TRPC1/4/5
channels through direct molecular interaction with the channels
and are consistent with the hypothesis that Pico145 and AM237
bind to a well-defined, high-affinity-binding site essential to
TRPC1/4/5 channel gating. Targeting this binding site may be a
promising strategy to develop further generations of potent and
selective TRPC1/4/5 chemical probes and drug candidates.
Several high-resolution TRPC structures have been determined
by single-particle cryo-electron microscopy (cryo-EM), including
zebrafish TRPC433, mouse TRPC434 and mouse TRPC535. To
date, TRPC6 is the only TRPC channel for which small-molecule-
bound structures have been published36,37. Here, we report the
structure of a TRPC1/4/5 channel in complex with a small-
molecule modulator: the homomeric TRPC5:C5 channel in
complex with Pico145. We found that Pico145 binds between the
trans-membrane domains of two TRPC5 subunits, where it dis-
places a phospholipid in a conserved lipid-binding site. Docking
and mutagenesis studies support these findings and provide
additional insights into the mode-of-action of xanthines as
modulators of TRPC5 and TRPC4 channels. In addition, we have
identified a putative intracellular zinc-binding site of TRPC5 that
is conserved within the TRPC family. This work provides a
rational basis for the design of new TRPC1/4/5 modulators and
suggests important functional roles for the conserved TRPC1/4/5
lipid and zinc-binding sites. Therefore, our findings may help
unravel physiological mechanisms of TRPC1/4/5 modulation,
and pave the way for structure-based TRPC1/4/5 drug discovery
efforts.
Results
Functional characterisation of C-terminally truncated human
TRPC5. For our structural studies, we engineered a human
TRPC5 construct containing an N-terminal maltose-binding
protein (MBP), followed by a PreScission protease site (PreS) and
a C-terminally truncated (Δ766–975) hTRPC5 (99% identical to
the analogous mTRPC5 construct35). Upon overexpression in
HEK 293 cells, TRPC5:C5 channels formed by this construct were
activated by EA (EC50 4.6 nM; cf. EC50 1.7 nM for full-length
hTRPC5) and inhibited by Pico145 (IC50 4.0 nM; cf. IC50 1.8 nM
for full-length hTRPC5) (Supplementary Fig. 1). These results
suggest MBP-PreS-hTRPC5Δ766–975 as a suitable construct for
structural determination of the xanthine-binding site.
Protein purification and quality control. Baculoviruses were
made for MBP-PreS-hTRPC5Δ766–975 expression and used to
transfect Freestyle™ 239-F Cells in suspension. MBP-tagged
TRPC5 was purified using a protocol adapted from Duan
et al.35, but with amphipol (PMAL-C8) exchange performed on-
resin and ultracentrifugation used in lieu of size exclusion chro-
matography to remove aggregated material. The protein was pure
according to SDS-PAGE analysis (Supplementary Fig. 2a), and
negative stain electron microscopy showed a monodisperse
sample with particles consistent in size with the expected tetra-
meric structure (Supplementary Fig. 2b). Further negative stain
analysis of the TRPC5 protein in the presence of Pico145 showed
a similar monodispersity with no evidence for aggregation or
disruption of the tetramer (Supplementary Fig. 2c).
Structure of a human TRPC5:C5 channel in complex with
Pico145. The cryo-EM structure of a human TRPC5:C5 channel
in the presence of Pico145 was determined with a global reso-
lution of 3.0 Å using C4 symmetry (Fig. 1, Table 1 and Supple-
mentary Fig. 3). To investigate whether there was heterogeneity
between the four subunits, the complex was also refined with no
symmetry imposed (C1 symmetry). The resulting TRPC5
structure showed no significant difference to the C4 refined
model, but the global resolution was lower (3.3 Å). The tetra-
meric structure of TRPC5 was built (based on the mTRPC5 apo
structure, PDB 6aei) and showed the typical TRPC fold: a large
intracellular domain made up of the N- and C termini of each
monomer, six trans-membrane helices per monomer and rela-
tively short extracellular loops (Fig. 1b). The N terminus (resi-
dues 1–366) folds into 4 ankyrin repeats, a helical linker domain
and the pre-S1-elbow domain. The first four trans-membrane
helices fold into a voltage sensing-like domain (VSLD); the next
two helices form the pore domain, together with the re-entrant
pore helix (E3 loop), which lines the ion permeation pathway.
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-01437-8
2 COMMUNICATIONS BIOLOGY |           (2020) 3:704 | https://doi.org/10.1038/s42003-020-01437-8 | www.nature.com/commsbio
The C terminus (residues 626 onwards) contains the TRP
domain and the coiled-coil domain, which is formed by one helix
from each monomer. The maltose-binding protein (MBP), pro-
tease site (PreS) and the first 16 amino acid residues of TRPC5
were not resolved in the map, likely because of flexibility. Like-
wise, residues 37–60, 74–95, 118–134, 273–285, 387–391,
665–702 and 734–765 were not modelled due to them being
poorly resolved. All residues that were not modelled are found in
the intracellular domain or extracellular loop 1; the trans-
membrane helices and the other extracellular loops were mod-
elled into the electron density.
Comparison of our TRPC5 structure to the previously reported
2.8 Å mTRPC5 apo structure (PDB 6aei)35 revealed a backbone
(Cα) RMSD of 0.81 Å showing a similar overall structure,
consistent with both being in the closed state. There were, however,
several notable local differences between the apo and Pico145-
bound structures (Supplementary Fig. 4a, b). In our structure, the
coiled-coil domain was less well ordered, and residues 734–759
could not be fit with confidence (and were therefore not included in
our model). However, the quality of our map was such that
additional residues could be built within the region 175–187, and
that residues 172–174 could be placed with greater accuracy. This
region showed that histidine 172 and cysteines 176, 178 and 181 all
point towards a central density, consistent with metal ion binding
(Figs. 1b and 5; see below for details). In addition, there was a
notable difference in the non-protein density between the apo and
Pico145-bound structures, as discussed below.
Pico145 binds to a conserved lipid-binding site of TRPC5.
Comparison of the cryo-EM structure of TRPC5:Pico145 to
published mTRPC535 and mTRPC434 apo structures showed
clear differences in one of the lipid-binding sites (Fig. 2a–c). In
the mTRPC5 apo structure, a density with a characteristic lipid
U-shape was observed close to the E3 re-entrant loop (Fig. 2b).
This density was ascribed to a phospholipid (postulated to be a
phosphatidic acid or ceramide-1-phosphate)35 that interacts with
the LFW motif, which is conserved in the TRPC family (Sup-
plementary Table 1). Indeed, a similar density is present in the
mTRPC4 structure (Fig. 2c). The hTRPC336,38 and hTRPC636,37
structures contain lipids that interact with their LFW motifs as
well, but with altered geometry (Supplementary Fig. 5). Our
TRPC5:Pico145 structure also showed density in this region.
However, the shape of this density was strikingly different to that
in the mTRPC5 and mTRPC4 apo structures (Fig. 2a–c): in our
structure, no density was observed for one of the lipid tails, and
additional density was found between residues Q573, F569 and
L572. Although this density was not consistent with a bound
lipid, its shape and size were consistent with the presence of a
molecule of Pico145. Indeed, modelling of Pico145 into this
density gave an excellent fit (Fig. 3a). Similar to the phospholipid
in the mTRPC5 and mTRPC4 apo structure, Pico145 (Fig. 3b)
was observed between two TRPC5 monomers, with four mole-
cules of Pico145 per TRPC5 tetramer. This was observed in both








Fig. 1 Structure of human TRPC5 in complex with Pico145. a Cryo-EM density map of TRPC5:Pico145 (contour level: 0.0373). b Model of TRPC5:Pico145
coloured by monomer, showing the typical TRP channel domain swap architecture. Dashed lines indicate the predicted position of the lipid bilayer. Insets
show one of the four Pico145-binding sites (between trans-membrane domains of the blue and orange TRPC5 monomers) and one of the four putative
intracellular zinc-binding sites (in the magenta monomer). c Representative fit of TRPC5:Pico145 model b into the experimental density a showing helical
regions spanning residues 193–234 (contour level: 0.0423).
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Fitting Pico145 into the density shows that most of the TRPC5
residues interacting with the inhibitor are from helix S5 and the
pore helix of the monomer on the right (monomer 1; Fig. 3a;
orange). The 3-hydroxypropyl substituent on N-1 of Pico145
interacts with the side chains of W577 and Q573, apparently
substituting for the phospholipid phosphate group in the apo
structures. Pico145’s xanthine core π-stacks with F576, and
several residues (including L521, Y524, C525 and V579) interact
with the 3-(trifluoromethoxy)phenoxy substituent on C8 of
Pico145. The 4-chlorobenzyl substituent on N-7 of Pico145
Fig. 2 Pico145 binds to a conserved TRPC4/5 lipid-binding site. a Density observed in our hTRPC5:Pico145 structure (100 µM Pico145; contour level:
0.0621). b Equivalent density in the published mTRPC5 apo structure (PDB 6aei, EMDB 9615) that was modelled as a phospholipid (contour level: 0.0510).
c The same site in the published mTRPC4 structure (PDB 5z96, EMDB 6901; contour level: 0.0331).
Table 1 Cryo-EM data collection, refinement and validation statistics.
2 mgml−1 hTRPC5 1 mgml−1 hTRPC5 1 mgml−1 hTRPC5
100 µM Pico145 (EMDB-10903) (PDB 6ysn) 50 µM Pico145 (EMDB-10909) 20 µM ZnCl2 (EMDB-10910)
Data collection and processing
Magnification 130,000 130,000 130,000
Voltage (kV) 300 300 300
Electron exposure (e–/Å2) 75 60 60
Defocus range (μm) −1 to −3 −1 to −3 −1 to −3
Pixel size (Å) 1.07 1.07 1.07
Symmetry imposed C4 C4 C4
Initial particle images (no.) 612,983 536,348 552,075
Final particle images (no.) 158,111 158,548 228,615
Map resolution (Å) 3.0 2.9 2.8
FSC threshold 0.143 0.143 0.143
Map resolution range (Å) 2.8–3.6 2.7–3.5 2.6–3.5
Refinement
Initial model used (PDB code) 6aei
Model resolution (Å) 3.0
FSC threshold 0.143
Model resolution range (Å) 2.8–3.6









Bond lengths (Å) 0.005
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points upwards, away from the lipid site, making a non-polar
interaction with L572. Pico145 also makes additional interactions
with helix S6 of the monomer on the left (monomer 2; Fig. 3a;
blue): Pico145 interacts with T603 and packs against G606, and
several hydrophobic amino acids (V610 and V614) interact with
Pico145’s 3-(trifluoromethoxy)phenoxy substituent. It should be
noted that the local resolution of the cryo-EM map at the core
of the TRPC5 channel, including the Pico145-binding site, was
better than 2.9 Å, making the fit unambiguous (Supplementary
Fig. 3).
During the optimisation of conditions for TRPC5:Pico145
cryo-grid preparation, we varied concentrations of TRPC5 and
Pico145. As part of this process, an additional structure of TRPC5
in the presence of Pico145 was solved with TRPC5 at 1 mgml−1
and Pico145 at 50 µM (compared to 2 mgml−1 TRPC5 and 100
µM Pico145 in the structure described above) to a global
resolution of 2.9 Å. The density around the Pico145-binding site
in this structure showed features consistent with both the bound
phospholipid and Pico145, suggesting partial occupancy under
these conditions (Supplementary Fig. 6a–c). This observation
may seem counter-intuitive, given the high potency of Pico145
and the fact that TRPC5:Pico145 ratios were identical in both
samples. A reason could be that binding kinetics of Pico145 to
purified TRPC5:C5 in amphipol may differ from those in the
cellular context. These data further support the observation that
Pico145 can displace each of the four phospholipids bound to a
tetrameric TRPC5 channel.
Docking of xanthines into TRPC5 and TRPC4 channel struc-
tures. To further investigate the Pico145-binding site of TRPC5
we conducted docking experiments, using our TRPC5:Pico145
cryo-EM structure in which the coordinates for Pico145 were
removed. Docking of Pico145 into a 36×36×36 Å grid around the
Pico145-binding site produced three poses with similar predicted
binding energies. These poses are almost identical to each other
(Supplementary Fig. 7a) and to the pose of Pico145 modelled in
our cryo-EM structure (Fig. 3c), giving confidence in the docking
procedure and further validation to the observed density being
assigned to Pico145. The lowest energy pose suggests that the 3-
hydroxypropyl substituent at N-1 of Pico145 makes two hydro-
gen bonds, donating a hydrogen bond to the carbonyl of the side
chain of Q573 and accepting a hydrogen bond from the indole of
W577 (Fig. 3d and Supplementary Fig. 7b). This 3-hydroxypropyl
substituent occupies a position similar to the phosphate head
group of the phospholipid in other structures. Consistent with
our TRPC5:Pico145 structure, all three poses show a π-stacking
interaction between F576 and the xanthine core of Pico145
(Fig. 3d and Supplementary Fig. 7). Although the positively
charged R557 is nearby, no significant interactions with this
residue appear to take place. The xanthine core of Pico145 and
the hydrophobic tails overlay almost perfectly in all three docked
poses (Supplementary Fig. 7a). The main difference between
poses is in the conformation of the 3-hydroxypropyl substituent,
suggesting it is flexible in the TRPC5-binding pocket, where it
may form hydrogen bonds with different TRPC5 residues.
Structural alteration of the docked Pico145 in TRPC5 to the
related xanthine AM237 (by addition of a chlorine atom) resulted
in a potential clash with L521 (Supplementary Fig. 8), suggesting
a structural rearrangement is required for AM237 to bind to
TRPC5. This could explain why Pico145 is an inhibitor of














Fig. 3 Analysis of the Pico145-binding site of TRPC5. a The refined structure of the Pico145-binding site within the cryo-EM density map (grey; contour
level 0.0583). The binding site spans two monomers: monomer 1 is shown in orange and monomer 2 is shown in blue; Pico145 is shown in magenta. Key
residues in the binding site (L521, Y524, C525, L572, Q573, W577, T603, G606 and V610) are labelled. b Chemical structure of Pico145 with the
numbering of the xanthine core. c An overlay of the top docking pose of Pico145 (peach) and our fitted Pico145 molecule (magenta). The top three docking
poses are shown in Supplementary Fig. 7. d The top-scoring docking pose suggests that Pico145 hydrogen bonds to Q573 and W577 (dashed blue lines)
and π-stacks with F576 (dashed black line).
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Pico145 is also a potent inhibitor of other TRPC1/4/5
channels24,25, including TRPC4:C4, for which a structure is
available, and which has a lipid-binding site that is near-identical
to that of TRPC5:C5 in terms of shape, bound phospholipid and
residues lining the pocket (Supplementary Fig. 5b vs Supplemen-
tary Fig. 5c). Importantly, the TRPC5 residues predicted to
interact with Pico145 are highly conserved in TRPC4, with the
only difference being that V579 in TRPC5 is isoleucine in TRPC4
(Supplementary Table 1). In order to test if Pico145 would be able
to bind in the lipid-binding site of TRPC4:C4, we next docked
Pico145 into the published mTRPC4 apo structure (PDB 5z96;
the phospholipid was removed before docking). The docking
suggests that Pico145 adopts a similar pose in TRPC4 and
TRPC5, making similar interactions with conserved residues,
particularly residues equivalent to the TRPC5 residues Q573,
F576 and W577 (Supplementary Fig. 9). These data suggest that
the binding site of Pico145 is conserved between TRPC4 and
TRPC5 channels.
Mutations in the xanthine-binding site alter the response of
TRPC5 to AM237. TRPC4 and TRPC5 channels (including
heteromeric TRPC1/4/5 channels containing TRPC1) are
modulated by the xanthines Pico145 and AM237, whereas
TRPC3/6/7 channels are not24,25. This is despite the high
sequence similarity between TRPC proteins around the xanthine/
lipid-binding sites of TRPC4 and TRPC5 channels (Supplemen-
tary Table 1). According to our structural modelling and docking,
several residues were predicted to be important for binding of
xanthines to TRPC5, and we decided to make and test three
TRPC5 variants: Q573T, F576A and W577A (Fig. 3d and
Table 2). Q573 is conserved between TRPC4 and TRPC5, but the
analogous residues in TRPC1 and TRPC3/6/7 are phenylalanine
and lysine, respectively (Supplementary Table 1). Q573T was
chosen because threonine and glutamine are both hydrophilic
amino acids with the propensity to form hydrogen bonds, but
with altered geometries, which might affect xanthine binding.
F576 and W577 are fully conserved TRPC residues that appear to
interact with the co-purified lipid in TRPC336,38, TRPC636,37,
TRPC434 and TRPC535 structures (Supplementary Fig. 5), and
therefore could be important for function or molecular interac-
tions. F576A should still be sufficiently hydrophobic to be stable
in the membrane environment, but would not be able to π-stack
with the xanthine core of Pico145/AM237. W577A would also
retain the hydrophobic character at this position but would lose
the ability of the W577 indole NH to act as a hydrogen bond
donor to the 3-hydroxypropyl group of Pico145/AM237.
The constructs were tested using fluorometric intracellular
calcium ([Ca2+]i) measurements (Fig. 4). Activation by EA11 was
used to show that TRPC5 variants were expressed and formed
functional TRPC5:C5 channels. The inhibitory potency of
Pico145 on TRPC1/4/5 channels is dependent on the EA
concentration used in assays24, which was expected to complicate
the analysis of Pico145 responses of TRPC5 variants. Other
commonly used TRPC5:C5 activators such as S1P and carbachol
(at least partially) act through intracellular signalling, and may
interfere with the composition of phospholipids bound to TRPC5,
while Gd3+ has complex effects in the presence of Pico14524.
Therefore, we decided to test TRPC5 responses to AM237, which
is thought to occupy the same binding site as Pico145 (see above
and refs. 31,32). Mutations that resulted in TRPC5 activation by
EA, but not by AM237, were likely to reveal residues contributing
to xanthine binding. Wild-type TRPC5 was activated by EA (EC50
5.7 nM) and AM237 (EC50 10.6 nM) (Fig. 4a–c). Both EA (EC50
260 nM) and AM237 (EC50 110 nM) activated the TRPC5Q573T
variant (Fig. 4d–f), but potencies of both activators were lower by
at least an order of magnitude compared to wild-type TRPC5 (46-
fold for EA and 10-fold for AM237; Table 2). TRPC5F576A
(Fig. 4g–i) and TRPC5W577A (Fig. 4j–l) could be activated by EA,
but again much higher EA concentrations were needed (EC50
values of ≥1400 and 370 nM, respectively; Fig. 4i, l). However,
neither TRPC5 variant could be activated by AM237 (no response
up to 5 µM AM237; Fig. 4h, k), suggesting that F576 and W577
are key residues for the binding/gating of TRPC5 by AM237.
Note that in wild-type HEK 293 cells, application of up to 5 µM of
EA or AM237 did not result in increases in [Ca2+]i (Supple-
mentary Fig. 10), demonstrating that the signals detected in Fig. 4
are the result of TRPC5 channel activation rather than TRPC5-
independent Ca2+ handling processes. These results are con-
sistent with our structural data and modelling/docking. In
addition, the large decreases in EA potency seen in F576A
(≥245-fold; Table 2) and W577A (65-fold; Table 2) may explain
why Duan et al.35 found that the mTRPC5 variant (F576A,
W577A) was unresponsive to 100 nM EA.
The TRPC5:Pico145 structure reveals a putative, conserved
zinc-binding site. Our TRPC5 cryo-EM map allowed residues
172–187 to be resolved and built. This region, which was not built
into the previously published mTRPC5 apo structure35, includes
residues H172, C176, C178 and C181. The nature of the amino
acids and the directionality of their thiol and imidazole sub-
stituents suggested the presence of a metal-binding site. A PDB
motif query search, using hTRPC5 residues 172–181
(HXXXCXCXXC), revealed the presence of a similar binding site
in the PHD domain of the zinc-binding E3 ubiquitin ligase
UHRF1 (PDB 3zvz) where the motif coordinates a Zn2+ ion.
Manual overlay of this structure with our TRPC5 structure
revealed a close alignment of residues (Fig. 5). The importance of
this site is reflected by the complete conservation of these residues
in the TRPC family (Supplementary Fig. 11). In addition, Park
et al.23 recently reported that intracellular application of Zn2+
(micromolar concentrations) can open neuronal TRPC5 channels
through an unknown mechanism. Therefore, we solved an
additional structure of TRPC5 (1 mgml−1; ca. 7 µM of TRPC5
monomer) in the presence of ZnCl2 (final concentration 20 µM)
(Supplementary Fig. 3c). This structure, which was determined to
a global resolution of 2.8 Å, showed that the addition of ZnCl2 did
not cause significant structural changes compared to our TRPC5:
Pico145 structure described above. Again, the C-terminal coiled-
coiled tail was more disordered than in the published mTRPC5
apo structure, suggesting that our slight alterations of the con-
struct or purification protocol may be the cause of this disorder
(Supplementary Fig. 4). The lipid/xanthine-binding site showed a
Table 2 Summary of data in Fig. 4.
TRPC5 variant Residue in TRPC4/1/3/6/7 EA EC50 (nM) AM237 EC50 (nM)
Wild-type 5.7 10.6
Q573T Q/F/K/K/K 260 110
F576A F/F/F/F/F ≥1400 No response up to 5 µM
W577A W/W/W/W/W 370 No response up to 5 µM
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non-protein density consistent with a phospholipid (Supple-
mentary Fig. 6a, c, d). In the zinc-binding domain, the densities
were similar (and partially disordered) in the TRPC5:Zn2+ and
TRPC5:Pico145 structures. Because of this disorder, and the
lower local resolution, we could not unambiguously identify the
density of the Zn2+ ion in either structure. These observations
may suggest that this region is flexible and/or that fewer than four
of the zinc-binding sites are occupied at any one time, even in the
presence of added ZnCl2. Interestingly, a structural alignment
showed that the putative zinc-binding motif is present in the
cryo-EM-derived structures of all TRPC channels; it was built
into the hTRPC336,38 and hTRPC636,37 structures, but not into
the mTRPC434 or mTRPC535 structures (Supplementary Fig. 11).
These findings suggest that TRPC channels have a conserved
intracellular zinc-binding site.
Discussion
The widely expressed TRPC1/4/5 channels have been implicated
in various physiological and pathological mechanisms and are an
emerging class of potential drug targets4,5,10,17. Our study pro-
vides structural insight into small-molecule modulation of a
TRPC1/4/5 channel. By determination of a 3.0 Å structure of the
TRPC5:C5 channel in complex with the TRPC1/4/5 inhibitor
Pico145, we show that Pico145 can bind to up to four lipid-
binding sites between TRPC5 subunits, where it displaces
Fig. 4 Mutations in the xanthine-binding site of TRPC5 affect responses to the xanthine-based TRPC5 agonist AM237. a, b, d, e, g, h, j, k
Representative traces from single 96-well plates (N= 3; error bars show standard deviations over technical replicates) showing changes of [Ca2+]i in
response to 0.32 nM to 5 µM of EA (a, d, g, j) or AM237 (b, e, h, k) in HEK 293 cells transiently expressing wild-type TRPC5-SYFP2 (a, b), TRPC5-
SYFP2Q573T (d, e), TRPC5-SYFP2F576A (g, h) or TRPC5-SYFP2W577A (j, k). c Concentration–response data for experiments in a and b (scatter plots showing
normalised data for three independent experiments each; n/N= 3/6). f Concentration–response data for experiments in d (scatter plot showing
normalised data for three independent experiments; n/N= 3/6) and e (scatter plot showing normalised data for two independent experiments; n/N= 2/
4). i Concentration–response data for experiments in g (scatter plot showing normalised data for two independent experiments; n/N= 2/4; because no
upper limit of the EA response of F576A could be determined, the EC50 for EA is unknown but can be estimated from the fitted curve to be at least 1400
nM; AM237 gave no response up to 5 µM). l Concentration–response data for experiments in j (scatter plot showing normalised data for two independent
experiments; n/N= 2/5; AM237 gave no response up to 5 µM). Responses were calculated at 240–300 s compared to [Ca2+]i at baseline (0–60 s).
Averages of technical repeats of each individual experiment were normalised to the maximum response and vehicle control (0 nM) for the independent
experiment, combined, and fit with GraphPad Prism 8 (variable slope, four-parameter logarithmic fit).
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phospholipids that interact with the channel’s pore helices, pre-
viously proposed to be ceramide-1-phosphate or a phosphatidic
acid35. Pico145 could be fit unambiguously into the non-protein
density between TRPC5 subunits, which was strikingly different
from the density in the corresponding sites of the published
mTRPC535 and mTRPC434 apo structures, and of our 2.8 Å
structure of TRPC5 determined in the presence of ZnCl2. Our
findings were further corroborated by a partially-occupied
TRPC5:Pico145 structure (showing density for both Pico145
and the phospholipid), molecular docking, and site-directed
mutagenesis. We hypothesise that Pico145 initially integrates with
the lipid membrane, before entering the lipid-binding site
between two TRPC5 subunits and replacing the bound phos-
pholipid. This hypothesis is consistent with the hydrophobic
nature of Pico145, and with the observation that the effect of
Pico145 is not as rapid as would be expected for a pore blocker 24.
The xanthines Pico145 and HC-070 are the most potent and
selective TRPC1/4/5 inhibitors to date24,25. However, three clo-
sely related xanthine derivatives, AM23731 and the photoaffinity
probes Pico145-DA and Pico145-DAAlk32, are partial agonists of
the homomeric TRPC5:C5 channel that inhibit other TRPC1/4/5
channels. Pico145 is a competitive antagonist of AM23731 and
concentration-dependently inhibits both activation and photo-
affinity labelling of TRPC5:C5 by Pico145-DAAlk32. These data
are consistent with the hypothesis that xanthine-based TRPC1/4/
5 modulators all bind to the same lipid-binding site of TRPC1/4/5
channels (this paper and refs. 31,32), where they can stabilise
either open or closed channel conformations depending on
xanthine substituent patterns and the composition of the specific
TRPC tetramer. Therefore, targeting the xanthine-binding site of
TRPC1/4/5 channels may allow the development of modulators
of specific TRPC channel tetramers, a major challenge in TRPC1/
4/5 pharmacology.
TRPC1/4/5 channels are modulated by endogenous and dietary
lipids, but the mechanisms are complex and incompletely
understood12,19–22. Lipids may affect TRPC1/4/5 channels
indirectly, e.g., the phospholipid S1P can activate channels (at
least in part) through G-protein signalling39. However, more
direct mechanisms are possible as well, e.g., lysopho-
sphatidylcholine (LPC) activates TRPC5 in excised outside-out
patches in the absence of GTP40. Such mechanisms may involve
direct molecular interactions and/or changes to the membrane
environment of TRPC1/4/5 channels. The TRPC5 lipid-binding
site that Pico145 interacts with is highly conserved within the
TRPC family (Supplementary Table 1). Bound (phospho)lipids
have been found in this site in structures of hTRPC336,38,
mTRPC434, mTRPC535 and hTRPC636,37, and the TRPC6 acti-
vator AM-0883 displaces the ordered lipid bound in this site near
the P-loop of hTRPC6 (Supplementary Fig. 5f)37. The hTRPC5
residues F576 and W577 are conserved throughout the TRPC
family and are likely to be responsible for lipid binding. Muta-
tions of these residues resulted in TRPC5 variants that displayed
lower sensitivity to EA and lacked a response to AM237. This
suggests that EA may bind in the lipid/xanthine-binding site as
well, which is consistent with the observation that the potency of
Pico145 is dependent on the concentration of EA used in
assays24. Our study suggests that binding of (phospho)lipids to
the conserved TRPC lipid-binding sites is a dynamic, reversible
process that may have a direct functional effect on channel gating,
and that this site can be targeted by TRPC1/4/5 activators as well
as inhibitors. However, further studies are required to fully
understand the mechanisms of TRPC1/4/5 channel binding and
gating by (phospho)lipids and different small-molecule TRPC1/4/
5 activators such as EA.
Intracellular Zn2+-dependent activation of TRPC5 channels
was recently reported to contribute to oxidative neuronal death23,
but the molecular mechanism of Zn2+ regulation of TRPC5 was
not determined. We have identified a putative intracellular zinc-
binding site of TRPC5, which is conserved in all TRPC channels.
Cryo-EM of TRPC5 in the presence of ZnCl2 resulted in a further
TRPC structure determined to a resolution of 2.8 Å. Presence of
ZnCl2 did not change the overall structure compared to TRPC5:
Pico145, and the density of the Zn2+ ion could not be unam-
biguously identified in either structure. These observations sug-
gest flexibility of the region or partial maximum occupancy of the
zinc-binding site, and may indicate that zinc is already bound in
TRPC5:Pico145, or that the role of zinc in TRPC5 modulation is
subtle. A subtle role of Zn2+ in TRPC5 modulation would also be
consistent with the delayed Zn2+-mediated [Ca2+]i increase
observed in calcium imaging experiments, and the small TRPC5
currents evoked by intracellular application of ZnCl223. Part of
the putative zinc-binding site has also been implicated in TRPC5
glutathionylation: mutation of C176, C178 or C181 prevented
TRPC5 opening in response to glutathionylation41. A separate
report proposed that palmitoylation of C181 is required for
correct trafficking of TRPC5 to the plasma membrane in striatal
neurons42. These data suggest that this small domain may be an
important regulatory node of TRPC channels and that further
experiments are needed to fully understand its role in TRPC
channel biology.
To the best of our knowledge, our data provide the first
structural insight into TRPC1/4/5 channel modulation and sug-
gest direct modulatory roles for (phospho)lipids and Zn2+ ions.
Our data are consistent with the description of a structure of
hTRPC5 in complex with the xanthine HC-070 in a non-peer-
reviewed study by Song et al.43, which appeared shortly after the
initial disclosure of our study on bioRxiv. These studies lay the
foundations for the structure-based design of TRPC1/4/5 mod-
ulators, and may therefore support the development of new
TRPC1/4/5 chemical probes and drug candidates for an
increasing number of therapeutic areas.
Methods
Plasmids. All plasmids were cloned using NEBuilder HiFi DNA Assembly Master
Mix (New England Biolabs) and mutations were made using the Q5 Site-directed
mutagenesis kit (New England Biolabs). The BacMam vector was a kind gift from
Professor Eric Gouaux (Vollum Institute)44. Briefly, human TRPC5 was cloned as a
C-terminally truncated form (Δ766–975) with an N-terminal maltose-binding
protein tag followed by a PreScission protease cleavage site (as in ref. 35) using





Fig. 5 Structure alignment of hTRPC5 and hURF1 is consistent with the
identification of a TRPC5 zinc-binding site. Sequence alignment revealed
that the Cys3-His1 motif closely matched that of the PHD finger of human
UHRF1 (an unrelated zinc-binding protein). Manual alignment was
performed between hTRPC5 (orange) and hUHRF1 (PDB 3zvz; wheat).
hTRPC5 residues forming the putative zinc-binding site have been
annotated.
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described V455M mutation45. Point mutations to the xanthine-binding site were
introduced into TRPC5-SYFP2 in pcDNA4. Bacmids and baculoviruses were
produced according to the Bac-to-Bac protocol (Invitrogen).
Protein expression and purification. P2 virus was added to 2.0 million per ml of
Freestyle™ 293-F Cells (ThemoFisher Scientific) in Gibco FreeStyle 293 Expression
Medium (Invitrogen) at a final volume of 10% at 37 °C and 5% CO2. After 24 h, 5
mM sodium butyrate (Sigma Aldrich) was added and the temperature was lowered
to 30 °C. After a further 48 h, cells were harvested by centrifugation and frozen. The
protein purification protocol was adapted from Duan et al.35. Unless stated
otherwise, all detergents (and amphipol PMAL-C8) were supplied by Generon. For
a typical purification, a 200 ml cell pellet was thawed and resuspended in 20 ml of
1% DDM, 0.1% CHS, 150 mM NaCl (Sigma Aldrich), 30 mM HEPES (Sigma
Aldrich) pH 7.5, 1 mM DTT (Fisher Scientific Ltd) and protease inhibitor cocktail
(Sigma Aldrich), and incubated by rotating at 4 °C for 1 h. After ultracentrifugation
at 100,000×g for 1 h at 4 °C, the supernatant was incubated with 400 µl bed volume
of pre-washed amylose resin (New England Biolabs) for 18 h, rotating at 4 °C. The
resin was washed with 20 ml of 0.1 % digitonin and 0.01% CHS, 150 mM NaCl, 30
mM HEPES pH 7.5, 1 mM DTT. The resin was resuspended in 10 ml of 0.1%
PMAL-C8, 150 mM NaCl, 30 mM HEPES pH 7.5, 1 mM DTT and rotated for 4 h
at 4 °C. 100 mg of Biobeads (Bio-rad) were then added and incubated for 18 h,
rotating at 4 °C, to remove detergents. The resin was washed with 20 ml of buffer
containing no detergent (150 mM NaCl, 30 mM HEPES pH 7.5, 1 mM DTT)
before eluting in 5 ml of the same buffer plus 40 mM maltose (Sigma Aldrich). The
eluate was subjected to ultracentrifugation at 100,000×g for 1 h at 4 °C to remove
any precipitated material and the supernatant was concentrated to the required
concentration with 100 kDa cut off vivaspin 500 concentrators (Sigma Aldrich). In
a typical purification protocol, 50–100 µg of purified TRPC5 was produced from
200 ml of cell suspension.
Negative stain electron microscopy. Sample quality was assessed by negative
stain electron microscopy. Briefly, carbon-coated grids were glow-discharged for
40 s in a Pelco glow discharge unit. After glow-discharging, 3 μl of purified TRPC5
at 0.04 mgml−1 was added to the grid and the sample was stained as follows46. The
grid was incubated with TRPC5 at room temperature for 30 s and the excess
protein solution was wicked away using filter paper (Whatman Grade 1). This was
followed by two successive incubations with uranyl acetate stain, in each of which
3 μl of 1% uranyl acetate was applied to the grid, followed by 1 min incubation and
wicking away of excess liquid. The grid was then left to air dry. For Pico145-
containing grids, Pico145 (10 mM in DMSO) was added to 2 mgml−1 purified
TRPC5 to a final concentration of 100 µM, which was subsequently diluted 50-fold
in detergent-free wash buffer, resulting in a final concentration of 2 µM Pico145
and 0.04 mgml−1 TRPC5. Negative stain grids were imaged using a Technai T12
microscope fitted with a LaB6 filament operating at 120 kV with a nominal mag-
nification of ×49,000 on a 2 k × 2 K Gatan CCD camera.
Sample preparation and data collection. Pico145 (final concentration of 100 µM,
from a 10 mM DMSO stock; final DMSO concentration 1%) was added to purified
TRPC5 in PMAL-C8 at 2.0 mg ml−1. A 3 µl aliquot of the sample was applied to a
Quantifoil Cu R1.2/1.3, 300 mesh holey carbon grid, which had been glow-
discharged for 30 s using a Pelco glow discharge unit. An FEI Vitribot was used to
blot the grids for 6 s (blot force 6) at 100% humidity and 4 °C before plunging into
liquid ethane. The grids were loaded into an FEI Titan Krios transmission electron
microscope (Astbury Biostructure Laboratory, University of Leeds) operating at
300 kV, fitted with a Gatan K2 direct electron detector operating in counting mode.
Automated data collection was carried out using EPU software (2.2) and Digital
Micrograph (3.23) with a defocus range of −1 to −3 µm. A total of 3,482
micrographs were collected with a pixel size of 1.07 Å. The total dose, 75 e−Å−2,
was acquired by use of a dose rate of 8.64 e− pixel−1 s−1 (7.58 e−Å−2 s−1) across
40 frames for 10 s total exposure time. The parameters for the structures in the
presence of ZnCl2 or 50 uM Pico145 used 1 mgml−1 final protein concentration
and used the same EPU software with a defocus range of −1 to −3 µm. Micro-
graphs were collected with a pixel size of 1.07 Å. The total dose, 60 e−Å−2, was
acquired by using a dose rate of 8.54 e− pixel−1·s−1 (7.49 e−Å−2 s−1) across 40
frames for 8 s total exposure time.
Image processing. An overview of the image processing protocol is shown in
Supplementary Fig. 12. All processing was completed in Relion-3.0.7 unless stated
otherwise47. The initial drift and beam-induced motion were corrected for using
MotionCor248, and CTf estimation was performed using Gctf49. Automated par-
ticle picking was performed in crYOLO (1.3.5)50 using the general model. For the
Pico145-bound structure, this resulted in a particle stack containing 612,983 par-
ticles that were imported into Relion-3.0.7. An initial round of 2D classification
resulted in a particle stack consisting of 519,962 particles. A 3D initial model was
generated in Relion and low-pass filtered to 60 Å when used in 3D classification.
The best class, consisting of 266,887 particles, was taken forward and refined with
C4 symmetry imposed to give a global resolution of 3.3 Å after post-processing,
with resolutions estimated by the gold standard FSC= 0.143 criterion. Three
iterative rounds of CTF refinement51 and particle polishing were completed, which
improved the resolution of the map to 3.1 Å. The polished particles underwent two
further rounds of 3D classification resulting in a particle stack containing 158,111
particles that were refined to 3.0 Å. A local resolution map was calculated in Relion
which showed that the core of the structure was at a higher resolution (2.8 Å) than
the global average. For the structure in the presence of ZnCl2, crYOLO picked
552,075 particles, which was reduced to 479,810 upon 2D classification. 3D clas-
sification further reduced this to 228,615 particles, which were refined and post-
processed, resulting in a 3.1 Å structure. After three iterative rounds of CTF
refinement and particle polishing, the resolution of the map was improved to 2.8 Å
—further 3D classification did not improve the map. For the 50 µM (partial
occupancy) Pico145 structure, micrographs were subjected to crYOLO particle
picking (536,348 particles), followed by 2D classification (509,928 particles), 3D
classification (158,548 particles). 3D classified particles were subjected to refine-
ment and post-processing, resulting in a 3.1 Å structure. Three rounds of CTF
refinement and particle polishing improved the overall resolution to 2.9 Å—further
3D classification did not improve the map.
Creation of PDB file. The model of TRPC5 with 100 µM Pico145 was produced by
the manual fitting of 6aei into the model. Several rounds of real-space refinement
in Phenix (1.16 −3549)52 were performed before fitting Pico145 into the map in
WinCoot (0.8.9.2)53. Models and maps were visualised and figures prepared in
UCSF Chimera (1.13.1)54.
Docking studies. The region of the TRPC5 tetrameric structure assigned for
docking studies was chosen based upon residues identified to be close Pico145 in
our TRPC5:Pico145 structure (Y524, L572, Q573, F576, W577, V579, F599, Y603
and V614). A 25 Å clip of the TRPC5 structure around these residues was termed
as the receptor for docking studies using Glide (Schrödinger Release 2019-4, Glide,
Schrödinger, LLC, New York, NY, 2020)55. The TRPC5 pdb file was prepared using
the Protein Preparation Wizard in the Maestro Graphical User Interface (GUI).
This aimed to remove any steric clashes of amino acid side chains and optimise the
position of hydrogen atoms to facilitate docking studies. The receptor grid was
generated using Schrödinger software, allowing docking of ligands in a 36×36×36 Å
grid. The Pico145 ligand was prepared using the OMEGA module56 of OpenEye
software (OMEGA version 2.5.1.4 OpenEye Scientific Software, Santa Fe, NM;
http://www.eyesopen.com) to produce an energy-minimised 3D structure before
importing into the Maestro GUI. Docking of Pico145 was carried out using the
Glide module of Schrödinger software using the XP mode with flexible ligand
sampling and biased sampling of torsions for all predefined functional groups. Epik
state penalties were added to the docking score. A maximum of 10 poses for the
ligand was requested in the output file and post-docking minimisation was
carried out.
Intracellular Ca2+ measurements. Intracellular calcium ([Ca2+]i) was measured
using the ratiometric Ca2+ dye Fura-2. HEK 293 cells (ATCC, Teddington, UK)
were plated in 6-well plates at 1 million cells per well. The following day, cells were
transfected with 2 µg DNA using 6 µl of JetPrime (VWR International) according
to the manufacturer’s protocol. The next day cells were washed, trypsinised and
plated onto black, clear-bottom poly-D-lysine coated 96-well plates with 60,000
cells per well. 24 h after plating, the cells were loaded with the Fura-2 dye by
removal of media and addition of SBS (NaCl 130 mM, KCl 5 mM, glucose 8 mM,
HEPES 10 mM, MgCl2 1.2 mM and CaCl2 1.5 mM; all supplied by Sigma Aldrich)
containing 2 μM Fura-2 acetoxymethyl ester (Fura-2 AM; ThermoFisher Scientific)
and 0.01% pluronic acid (Merck) for 1 h at 37 °C. After this incubation, cells were
washed with fresh SBS and incubated at room temperature for a further 30 min.
SBS was then changed to recording buffer (SBS with 0.01% pluronic acid and 0.1%
DMSO to match compound buffer) immediately prior to experimentation. In the
case of inhibitor studies, the buffer was replaced with SBS with 0.01% pluronic acid
and the relevant inhibitor or vehicle. Cells were then incubated for 30 min prior to
the experiment. Measurements were carried out using a FlexStation and SoftMax
Pro 7 software (Molecular Devices, San Jose, CA), using excitation wavelengths of
340 and 380 nm, at an emission wavelength of 510 nm. ([Ca2+]i) recordings was
performed at room temperature at 5 s intervals for 300 s (unless stated otherwise).
EA or AM237 was added by the FlexStation from a compound plate (final DMSO
concentration 0.1%) after recording for 60 s. Responses were calculated at 240–300
s compared to the signal at baseline (0–60 s), and an average was taken within each
individual experiment. Averages from individual experiments were normalised
relative to the maximum signal for each TRPC5 variant/activator combination and
to the vehicle control, combined and fit (using a variable slope, 4-parameter
logarithmic fit) with GraphPad Prism 8 with [agonist] for EA or AM237, or
[inhibitor] for Pico145 vs response.
Statistics and reproducibility. For intracellular calcium recordings, n (the num-
ber of independent experiments, i.e. different plates with different batches of cells)
and N (the total number of replicates from n independent experiments) have been
defined in the figure legends.
Chemicals. Pico14524 and AM23731 were prepared according to previously
reported procedures. (−)-englerin A (EA) was obtained from PhytoLab
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(Vestenbergsgreuth, Germany). AM237, Pico145 and EA were made up as 10 mM
stocks in 100% DMSO, aliquots of which were stored at −20 °C (AM237 and
Pico145) or −80 °C (EA). Further dilutions of compounds were made in DMSO
and these were dissolved 1:1000 in a compound buffer (SBS+ 0.01% pluronic acid)
before being added to cells. Fura-2 AM (Invitrogen UK) was dissolved at 1 mM in
DMSO.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Protein sequences and structural data are available via the Protein Data Bank (PDB
6YSN) and the Electron Microscopy Data Bank (EMDB-10903, EMDB-10909 and
EMDB-10910). Raw data for intracellular calcium recordings (Fig. 4) are available in
Supplementary Data 1.
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